Latest Articles

Subject

Article
Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis
Imke Metz, Tim Beißbarth, David Ellenberger, et al.

February 02, 2016
Clinical/Scientific Notes
Degos disease mimicking primary vasculitis of the CNS
Sabrina Gmuca, Markus D. Boos, Amanda Treece, et al.

February 02, 2016
Article
Converging mediators from immune and trophic pathways to identify Parkinson disease dementia
Lih-Fen Lue, Christopher T. Schmitz, Noelle L. Snyder, et al.

January 27, 2016
Article
Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination
Yen Chih Lin, Paige Winokur, Andrew Blake, et al.

January 27, 2016
Article
Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
Nicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet, et al.

January 27, 2016
Editorial
Rising JCV-Ab index during natalizumab therapy for MSInauspicious for a highly efficacious drug
Adil Javed, Anthony T. Reder

January 27, 2016
Article
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
Harald Hegen, Indra Adrianto, Christopher J. Lessard, et al.

January 27, 2016
Article
Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis
Rohit Bakshi, Ada Yeste, Bonny Patel, et al.

January 27, 2016
Clinical/Scientific Notes
Autopsy-proven demyelination associated with infliximab treatment
Michael J. Bradshaw, Bret C. Mobley, Jeffrey P. Zwerner, et al.

January 27, 2016
Article
Alemtuzumab long-term immunologic effectTreg suppressor function increases up to 24 months
Stefania De Mercanti, Simona Rolla, Angele Cucci, et al.

January 21, 2016

Pages